Core Viewpoint - The news highlights ongoing legal actions against companies Zhongzhuang Construction and Luopute for false financial reporting, leading to investor claims and recent court victories for affected investors [1][4][5]. Group 1: Zhongzhuang Construction - Zhongzhuang Construction has been found guilty of false statements, resulting in a significant profit inflation from 2017 to 2021, with inflated profits of 18.33 million, 12.92 million, 43.99 million, 13.02 million, and 16.10 million yuan, representing 9.06%, 5.26%, 14.74%, 3.91%, and 8.88% of the reported profits for those years respectively [1][4]. - The company received an administrative penalty notice on April 19, 2025, confirming the misreporting of financial data in annual reports from 2017 to 2021 [1][4]. - Investors who purchased Zhongzhuang Construction shares between April 16, 2018, and December 16, 2023, are eligible to file claims [2][5]. Group 2: Luopute - Luopute has also been implicated in financial misconduct, with inflated revenues of 213.95 million yuan in 2020 (34.65% of reported revenue) and 111.73 million yuan in 2021 (15.42% of reported revenue), alongside profit inflation of 146.12 million yuan (81.21%) in 2020 and 20.75 million yuan (20.41%) in 2021 [2][5]. - The company reported a profit reduction of 73.10 million yuan in 2022, which accounted for 30.84% of the absolute value of reported profits [2][5]. - Investors who bought Luopute shares between April 20, 2021, and May 18, 2023, can still initiate claims, with a deadline approaching [3][6].

Core Viewpoint - The article discusses the ongoing legal actions against Ningke Biological (600165) for false statements and the implications for investors seeking compensation due to the company's financial misconduct [1][7]. Group 1: Ningke Biological's Legal Issues - Ningke Biological is facing a lawsuit for false statements, with a recent case submitted to the court by attorney Xu Feng [1][7]. - The company inflated its 2022 revenue by 76.59 million yuan and profit by 77.22 million yuan, representing 11.25% and 46.59% of its total revenue and profit, respectively [1][7]. - The company failed to timely disclose significant events, including major debts, frozen bank accounts, and the suspension of its subsidiary's main business [2][3][4]. Group 2: Investor Compensation Opportunities - Investors who purchased Ningke Biological shares between November 22, 2022, and April 6, 2023, or between April 28, 2023, and October 31, 2024, may initiate claims for compensation [5][9]. - The law firm is also handling claims for investors of Shandong Zhanggu (002598), which is under investigation for financial disclosure violations [5][10]. - Investors who bought Shandong Zhanggu shares before January 1, 2026, and sold or held them afterward are eligible to file for compensation [6][10].

Core Viewpoint - The article discusses the ongoing legal actions against Changyao Holdings (300391) for investor compensation due to financial misconduct, including false reporting of revenues and profits from 2021 to 2023 [1][2][3]. Group 1: Legal Proceedings - Changyao Holdings' investor compensation case has been accepted by the Wuhan Intermediate People's Court, with multiple previous filings also accepted [1]. - The law firm is continuing to accept compensation claims from other investors [1]. - There are precedents of investor victories in similar compensation cases against Changyao Holdings [1]. Group 2: Financial Misconduct - From 2021 to 2023, Changyao Holdings' subsidiaries fabricated inventory and sales documents, leading to inflated revenues of 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan, which represented 9.12%, 17.57%, and 19.51% of the reported revenues for those years respectively [2]. - The inflated total profits for the same years were 56.40 million yuan, 63.38 million yuan, and 43.71 million yuan, accounting for 35.62%, 88.23%, and 6.42% of the reported total profits [2]. - In 2022, the company also inflated profits by 4.55 million yuan due to improper loss recognition related to a project, which was 6.34% of the reported total profits for that year [2]. Group 3: Investor Compensation Eligibility - Investors who purchased Changyao Holdings stock between March 30, 2019, and April 30, 2024, and sold or held the stock after April 30, 2024, are eligible to file for compensation [3]. - Additionally, those who bought shares between April 28, 2022, and November 8, 2025, and sold or held after November 8, 2025, can also initiate claims [3].

Core Viewpoint - Long Pharmaceutical Holdings (长药控股) is facing legal actions due to false financial reporting and has been penalized by the China Securities Regulatory Commission (CSRC) for various violations, leading to potential compensation claims from affected investors [1][7]. Group 1: Legal Actions and Compensation Claims - The Wuhan Intermediate People's Court has accepted a compensation claim case against Long Pharmaceutical Holdings, with previous cases also being accepted, indicating ongoing legal proceedings [1][3]. - Investors who purchased Long Pharmaceutical Holdings stock between March 30, 2019, and April 30, 2024, or between April 28, 2022, and November 8, 2025, are eligible to file for compensation [3][9]. Group 2: Financial Misconduct - Long Pharmaceutical Holdings has been found to have inflated revenues and profits in its financial reports from 2021 to 2023, with reported inflated revenues of 215.32 million, 283.74 million, and 233.63 million yuan, representing 9.12%, 17.57%, and 19.51% of the disclosed revenues respectively [2][8]. - The company also inflated total profits by 56.40 million, 63.38 million, and 43.70 million yuan during the same periods, accounting for 35.62%, 88.23%, and 6.42% of the reported total profits [2][8]. Group 3: Related Company Violations - The subsidiary of Long Pharmaceutical Holdings, Hubei Changjiang Source Pharmaceutical Co., and Hubei Xinfeng Pharmaceutical Co. engaged in creating false inventory and sales documents, leading to the recognition of non-existent sales [2][8]. - The company failed to properly recognize losses related to a project in 2022, further contributing to the inflated profit figures in its annual report [2][8].

Group 1: Renzi Hang (任子行) Case - Renzi Hang's investor compensation case has been accepted by the Shenzhen Intermediate People's Court, with a first-instance victory for investors already received [1][5] - The company was found to have inflated operating income by 36,951,333.48 CNY, 48,435,351.70 CNY, and 26,929,607.08 CNY from 2020 to mid-2022, accounting for 4.21%, 6.97%, and 10.81% of reported amounts respectively [1][5] - The inflated total profit was reported as 19,406,901.32 CNY, 37,317,431.71 CNY, and 16,560,909.58 CNY, representing 85.93%, 70.03%, and 30.79% of the absolute values of reported amounts [1][5] Group 2: Yitong Century (宜通世纪) Case - Yitong Century's investor compensation case has been submitted to the court, with previous cases resulting in settlements for some investors [2][6] - The company was involved in a major asset restructuring in October 2016, acquiring 100% of Beitai Health for a total consideration of 1 billion CNY [2][6] - Beitai Health inflated its revenue by 9,734.39 million CNY, costs by 5,260.99 million CNY, and total profit by 4,083.86 million CNY from May 1 to December 31, 2017, which constituted 3.7%, 9.75%, and 15.67% of Yitong Century's reported figures [3][7]

Group 1 - The core issue involves a lawsuit against Yili Clean Energy (600277) for false statements, with the case submitted to the Hohhot Intermediate People's Court [1] - The company is accused of financial fraud, including inflating profits, assets, and revenues from 2016 to 2022, and providing guarantees to its controlling shareholder and related parties from 2017 to 2022 [1] - Yili Clean Energy is also alleged to have engaged in fraudulent bond issuance [1] Group 2 - Investors who purchased Yili Clean Energy stock between April 18, 2017, and April 24, 2024, and sold or held the stock after April 24, 2024, may initiate claims [2] - The law firm is also handling claims for Poly United (002037), which has already seen some investors compensated, with a court hearing scheduled for March 2, 2026 [2] - Poly United was found to have underreported bad debt provisions and inflated net profits significantly from 2019 to 2021, with specific figures indicating a 19.95% increase in net profit for 2019 and a 124.47% increase for 2021 [3][4]

Core Viewpoint - The article discusses the ongoing legal actions against Guangdian Network (600831) due to false statements that have led to investor claims, highlighting recent developments in the case and the potential for further claims by affected investors [1][3]. Group 1: Legal Developments - The investor claims against Guangdian Network have seen significant progress, with previous cases resulting in court filings and victories for investors [1][3]. - The law firm Shanghai Jiucheng, led by lawyer Xu Feng, is actively pursuing additional claims and accepting new clients for compensation [1][3]. Group 2: Financial Misconduct - Guangdian Network was found to have inflated its 2022 annual report profits by CNY 23.52 million, which is 118.95% of the reported audited profit of CNY 19.77 million [2][5]. - The company acknowledged accounting errors in its 2022 financial statements, which resulted in a shift from profit to loss after corrections were made [2][5]. Group 3: Investor Eligibility for Claims - Investors who purchased Guangdian Network shares between April 21, 2023, and December 26, 2023, and sold or held their shares after December 26, 2023, are eligible to file claims [3][5].

Core Viewpoint - The announcement from Lifan Technology (立方数科) indicates that the company has been found guilty of false statements, allowing affected investors to initiate claims for compensation [1][2]. Group 1: Legal Actions and Claims - Investors who purchased Lifan Technology stock between April 25, 2022, and April 29, 2025, and sold or continued to hold the stock after April 29, 2025, are eligible to file claims [2][6]. - The law firm Shanghai Jiucheng, led by attorney Xu Feng, is actively pursuing claims on behalf of investors and has already filed multiple cases in court [3][6]. Group 2: Violations and Financial Impact - Lifan Technology has been found to have inflated its operating income and costs through various means, including agency business, financing trade, and false trade [4][5]. - The financial discrepancies reported include: - In 2021, inflated operating income of 279,726,668.85 yuan, accounting for 50.09% of that year's revenue, and inflated operating costs of 277,114,254.09 yuan, making up 60.61% of that year's costs [5]. - In 2022, inflated operating income of 311,855,333.46 yuan, representing 51.67% of revenue, and inflated operating costs of 305,460,743.11 yuan, which is 53.54% of costs [5]. - In 2023, inflated operating income of 45,869,361.67 yuan, constituting 24.00% of revenue, and inflated operating costs of 45,227,946.58 yuan, accounting for 27.55% of costs [5].

Group 1 - The law firm Shanghai Jiucheng has successfully filed a lawsuit for investor claims against Yingfeituo (002528), with the Shenzhen Intermediate People's Court accepting the case [1] - Investors who purchased Yingfeituo stock between April 30, 2020, and April 30, 2024, and sold or continued to hold the stock after April 30, 2024, are eligible to initiate claims [2] - The China Securities Regulatory Commission (CSRC) has initiated a case against Yingfeituo for suspected violations of information disclosure laws [1] Group 2 - The law firm has also achieved a favorable ruling in a claim case for Ningke Biological (600165), with some investors already receiving compensation [2] - Ningke Biological's 2022 annual report was found to contain false records, inflating revenue by 76.5941 million and profit by 77.2220 million, which accounted for 11.25% and 46.59% of total revenue and profit, respectively [2] - Investors who bought Ningke Biological stock between November 22, 2022, and April 6, 2023, or between April 28, 2024, and October 31, 2024, are also eligible to file claims [3]

Group 1 - The core issue involves investor claims against Nuotai Bio (688076) due to false statements leading to ongoing legal proceedings [1][5] - The Shanghai Financial Court has accepted the case for investor claims against Nuotai Bio, with further claims being processed [1][5] - Nuotai Bio's 2021 annual report was found to contain false records, including a reported revenue of 30 million yuan from a technology transfer that lacked commercial substance, inflating total revenue by 30 million yuan and profit by 25.95 million yuan, which accounted for 20.64% of the reported profit [1][5] Group 2 - Investors who purchased Nuotai Bio shares between April 28, 2022, and October 24, 2024, and sold or held shares after October 24, 2024, are eligible to file claims [2][6] - The law firm is also handling claims for Century Huatong (002602), with a recent filing submitted to the Shaoxing Intermediate People's Court [2][6] - Century Huatong was found to have false records in its annual reports from 2018 to 2022, including fabricated software copyright transfer transactions and premature revenue recognition [3][7] Group 3 - Investors who bought Century Huatong shares between April 27, 2019, and July 25, 2023, and sold or held shares after July 25, 2023, can initiate claims [4][8] - The law firm has a history of successfully representing investors in similar cases, with many having received compensation [4][8]